 invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc NASDAQ: FSTX for 7.12 per share. The proposed acquisition values F-star at approximately 161 million. 